GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xenetic Biosciences Inc (NAS:XBIO) » Definitions » Shiller PE Ratio

Xenetic Biosciences (Xenetic Biosciences) Shiller PE Ratio : (As of Jun. 10, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Xenetic Biosciences Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Xenetic Biosciences Shiller PE Ratio Historical Data

The historical data trend for Xenetic Biosciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xenetic Biosciences Shiller PE Ratio Chart

Xenetic Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Xenetic Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Xenetic Biosciences's Shiller PE Ratio

For the Biotechnology subindustry, Xenetic Biosciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xenetic Biosciences's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Xenetic Biosciences's Shiller PE Ratio falls into.



Xenetic Biosciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Xenetic Biosciences's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Xenetic Biosciences's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.78/131.7762*131.7762
=-0.780

Current CPI (Mar. 2024) = 131.7762.

Xenetic Biosciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -79.200 100.560 -103.786
201409 -79.200 100.428 -103.922
201412 -158.401 99.070 -210.695
201503 -79.200 99.621 -104.764
201506 -32.400 100.684 -42.405
201509 -151.201 100.392 -198.470
201512 -103.200 99.792 -136.276
201603 -93.600 100.470 -122.765
201606 -734.403 101.688 -951.703
201609 -33.600 101.861 -43.468
201612 -36.000 101.863 -46.572
201703 -40.800 102.862 -52.269
201706 -40.800 103.349 -52.022
201709 -31.200 104.136 -39.481
201712 62.400 104.011 79.057
201803 -25.200 105.290 -31.539
201806 -27.800 106.317 -34.457
201809 -23.100 106.507 -28.581
201812 -20.800 105.998 -25.858
201903 -64.500 107.251 -79.250
201906 -15.600 108.070 -19.022
201909 -26.700 108.329 -32.479
201912 -1.929 108.420 -2.345
202003 -1.900 108.902 -2.299
202006 -1.500 108.767 -1.817
202009 -12.000 109.815 -14.400
202012 -1.500 109.897 -1.799
202103 -1.500 111.754 -1.769
202106 -1.300 114.631 -1.494
202109 -1.300 115.734 -1.480
202112 -1.400 117.630 -1.568
202203 -1.200 121.301 -1.304
202206 -1.900 125.017 -2.003
202209 -0.560 125.227 -0.589
202212 -0.970 125.222 -1.021
202303 -0.560 127.348 -0.579
202306 -0.690 128.729 -0.706
202309 -0.690 129.860 -0.700
202312 -0.770 129.419 -0.784
202403 -0.780 131.776 -0.780

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Xenetic Biosciences  (NAS:XBIO) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Xenetic Biosciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Xenetic Biosciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Xenetic Biosciences (Xenetic Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
945 Concord Street, Framingham, MA, USA, 01701
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
Executives
Grigory G. Borisenko director 40 SPEEN STREET, SUITE 102, FRAMINGHAM MA 01701
Alexey Andreevich Vinogradov director C/O XENETIC BIOSCIENCES, INC., 40 SPEEN STREET, FRAMINGHAM MA 01701
Adam Logal director OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
James Eric Callaway director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Dmitry Genkin director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
James F Parslow officer: Chief Financial Officer C/O XENETIC BIOSCIENCES, INC., 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Curtis Lockshin officer: Chief Scientific Officer 4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Benz Edward J. Jr director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Roger D. Kornberg director 345 WALSH ROAD, ATHERTON CA 94027
Darlene M Deptula-hicks director C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Jeffrey F Eisenberg director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Firdaus J. Dastoor director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Michael Scott Maguire director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Roman Knyazev director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Pharmsynthez Pjsc 10 percent owner 25 LITER KRASNOVO KURSANTA STREET, ST. PETERSBURG 1Z 197110